Your Best Stock

Sanofi SNY

US equityMarket cap rank #161Infectious Disease
$41.03
−$0.63 (-1.51%)
Market open · Sep 24, 1:10 pm ET
After hours $41.66 0.00%
Open$41.24
Prev close$41.66
Day range$40.93 – $41.61
Volume1.82M
Market cap$98.31B
P/E (TTM)22.0
Dividend yield5.76%
  • Sanofi's (SNY.US) BTK inhibitor approved for market launch in China Zhitong Finance · 3 Sep 2026
  • Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Amgen (AMGN) and BrightSpring Health Services, Inc. (BTSG) TipRanks · 17 Sep 2026
  • Sanofi (SNY.US) has submitted a new indication for its long-acting RSV monoclonal antibody for marketing approval. Zhitong Finance · 7 Aug 2026
  • TD Cowen Maintains Sanofi(SNY.US) With Hold Rating, Maintains Target Price $57 Market news · 31 Aug 2026
  • Sanofi (SNYNF) Gets a Hold From J.P. Morgan TipRanks · 31 Jul 2026
  • 6-K: Sanofi Achieves Double - Digit Sales Growth in the Second Quarter, With a Steady Increase in Business Earnings per Share. 2025 Sales Guidance Is Now High Single-Digit Growth, At Upper End of Range SEC · 31 Jul 2026
  • Despite raising its earnings guidance in the new CEO's debut, Sanofi (SNY.US) saw its share price fall, as a pipeline drought of new drugs emerges as a critical vulnerability. Zhitong Finance · 30 Jul 2026
  • 6-K: Sanofi to Acquire Vigil Neuroscience, Inc., Adding a New Investigational Medicine to Treat Alzheimer's Disease to the Neurology Pipeline SEC · 22 May 2026
  • Sanofi | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.2%) SEC · 7 Feb 2026
  • Novavax | 8-K: Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment SEC · 4 Nov 2026
  • Sanofi | 6-K: Sanofi to Acquire Inhibrx, Inc., Adding Potential Best-in-Class Rare Disease Asset for Alpha-1 Antitrypsin Deficiency to Pipeline SEC · 23 Jan 2026
Scroll to Top